Plain-English translation of NCT04545242 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a steroid medication, to see if it can help patients with severe lung failure caused by infections recover better. Researchers want to find out whether a lower daily dose or a higher dose works best at reducing death and helping patients breathe on their own again. The study will compare two different dosing schedules over 10 days of treatment.
Severe lung infections can cause the lungs to become dangerously inflamed and fail, requiring a breathing machine. While steroids like this medication have shown promise in reducing inflammation and improving survival, doctors are not sure which dose is safest and most effective—so this trial will help answer that question.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to receive either a lower dose or a higher dose of the medication by intravenous injection (through an IV) for 10 days while you are on a breathing machine in the hospital. The study team will monitor your oxygen levels, breathing, and recovery during and after this 10-day treatment period to see how well the medication works and how safe it is.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Spain